Lexaria Bioscience Corp. balance sheet LEXX

Annual Quarterly

As of May 31, 2026, Lexaria Bioscience Corp. had total assets of $4.8 million and total liabilities of $437,091. Total assets were down 29.1% from a year earlier. Stockholders' equity was $4.7 million. It held $3.5 million in cash and investments against $86,714 of total debt, net cash of $3.4 million. The current ratio, current assets divided by current liabilities, was 10.60.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 May 31, 2026	FY 2025 Aug 31, 2025	FY 2024 Aug 31, 2024	FY 2023 Aug 31, 2023	FY 2022 Aug 31, 2022	FY 2021 Aug 31, 2021	FY 2020 Aug 31, 2020	FY 2019 Aug 31, 2019	FY 2018 Aug 31, 2018	FY 2017 Aug 31, 2017	FY 2016 Aug 31, 2016
Assets
Cash	4 -23.9%	2 -72.3%	6 +380.7%	1 -76.7%	6 -46.8%	11 +743.9%	1 +0.7%	1 -25.6%	2 -31.8%	3 +2612.1%	0 -64.1%
Short-term investments	0 -100.0%	0 -60.4%	0 -55.6%	0 -63.8%	0 -58.3%	1 +4215.7%	0 -69.9%	0 +532.6%	0	—	—
Long-term investments	—	0 +2384.7%	0	—	—	—	—	—	—	—	—
Cash and investments	4 -24.5%	2 -66.9%	7 +344.6%	1 -76.0%	6 -47.6%	12 +795.0%	1 -2.7%	1 -22.3%	2 -31.4%	3 +2612.1%	0 -64.1%
Receivables	0 -86.3%	0 +138.5%	0 +21.9%	0 -37.2%	0 -41.1%	0 +9.1%	0 +14.9%	0 +2.8%	0 +486.7%	0 -65.4%	0 +317.7%
Inventory	—	—	—	0 -100.0%	0 +29.6%	0 -74.6%	0 -8.3%	0 +46.0%	0 +29.9%	0 -50.1%	0 -19.8%
Total current assets	4 -30.0%	3 -56.1%	8 +267.1%	2 -69.2%	7 -43.9%	12 +546.1%	2 +5.9%	2 -20.4%	2 -18.3%	3 +448.0%	1 -24.4%
Property and equipment, net	0 -4.6%	0 -10.4%	0 +0.2%	0 -19.4%	0 -14.3%	0 -23.8%	0 -18.2%	1 +47698.1%	0 -33.4%	0 -25.0%	0
Total assets	5 -29.1%	4 -52.9%	9 +187.5%	3 -60.6%	8 -41.0%	13 +369.1%	3 +5.7%	3 +10.0%	2 -15.0%	3 +404.8%	1 -20.4%
Liabilities and equity
Total current liabilities	0 -74.2%	1 +35.8%	1 +310.6%	0 +38.0%	0 +26.6%	0 -32.2%	0 +22.4%	0 +322.8%	0 -52.7%	0 -78.7%	0 +687.1%
Total liabilities	0 -72.2%	2 +30.1%	1 +199.3%	0 +100.5%	0 -0.9%	0 -41.2%	0 +87.5%	0 +322.8%	0 -52.7%	0 -80.7%	0 +768.7%
Stockholders' equity	5 -14.7%	3 -62.8%	8 +164.0%	3 -61.7%	8 -40.1%	13 +434.4%	2 -0.3%	2 +4.3%	2 -13.7%	3 +940.4%	0 -65.6%
Debt
Lease liabilities	0 -25.6%	0 -20.4%	0 -16.2%	0 +228.0%	0 +26.9%	0 +9.3%	0	—	—	—	—
Total debt	0 -25.6%	0 -20.4%	0 -16.2%	0 +228.0%	0 +26.9%	0 +9.3%	0	—	—	—	—
Net cash	3 -24.4%	2 -67.9%	6 +389.6%	1 -78.5%	6 -47.8%	12 +817.1%	1	—	—	—	—
Ratios
Current ratio	10.60x	2.32x	7.18x	8.03x	35.96x	81.18x	8.53x	9.86x	52.34x	30.27x	1.18x
Debt to equity	0.02x	0.04x	0.02x	0.05x	0.01x	0.00x	0.01x	—	—	—	—
Return on equity	-163.18%	-398.10%	-72.11%	-218.94%	-91.45%	-30.36%	-164.55%	164.61%	276.36%	—	—
Return on assets	-161.71%	-285.07%	-65.35%	-216.11%	-92.79%	-30.35%	-144.42%	153.26%	271.40%	—	—
Book value per share	0.19	0.15	0.41	0.38	1.34	2.32	0.83	0.03	0.03	0.04	0.01

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: LEXX (Nasdaq)
Fiscal year ends: August 31
Incorporated in: NV
Headquarters: Kelowna, British Columbia, Canada
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1348362
Former names: Lexaria Corp. (until May 11, 2016); LEXARIA CORP. (until May 11, 2016)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.